A Total of 11 Poster Presentations Will Be Presented, Including Data from Two Pivotal Phase 3 Trials and 12-Month Safety Extension Trial of MIEBO™
. | June 8, 2023
/PRNewswire/ Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to.